VolitionRx (VNRX) Form 4: Rodney Rootsaert granted 15,223 RSUs, outlines vesting
Rhea-AI Filing Summary
Rodney Gerard Rootsaert, a director and officer (Secretary) of VolitionRx Limited (VNRX), reported an award of 15,223 restricted stock units (RSUs) on 08/15/2025 issued in lieu of cash compensation. The RSUs were granted at $0 price and will be earned in six approximately equal monthly installments beginning 09/01/2025. Once earned, the RSUs remain subject to additional time-based vesting in two installments of 7,612 and 7,611 on 11/01/2025 and 02/01/2026, respectively.
The filing shows Mr. Rootsaert directly beneficially owns 149,233 common shares following the award and has indirect beneficial ownership of 1,007,718 shares held by Concord International, Inc., where he is a controlling director with shared voting and dispositive power.
Positive
- Compensation aligned with service: RSUs vest over time, encouraging continued service through 02/01/2026
- Cash conservation: Award issued in lieu of cash compensation, preserving company cash resources
Negative
- Potential future dilution: 15,223 RSUs will convert to common shares upon vesting, increasing outstanding shares when settled
- Concentrated indirect ownership: 1,007,718 shares held by Concord International, Inc. indicate significant aggregated voting/dispositive power
Insights
TL;DR: Executive awarded RSUs in lieu of cash; structured earning and vesting schedule aligns compensation with continued service.
The award of 15,223 RSUs at no cash cost to the reporting person represents a common practice to conserve cash while aligning management incentives with shareholder outcomes. The award's staged earning (six monthly installments) followed by two time-based vesting dates creates layered service-based retention conditions through 02/01/2026. The disclosure of 1,007,718 indirectly held shares via Concord International, Inc. clarifies potential aggregation of influence; the report appropriately states the reporting persons controlling role and shared voting and dispositive power.
TL;DR: Non-cash RSU grant increases potential future share issuance but immediate dilution is limited until vesting/settlement.
Because the RSUs were granted for $0 and convert to common shares upon vesting, they represent potential future dilution of common stockholders when settled. The filing quantifies current beneficial ownership: 149,233 shares directly and 1,007,718 indirectly, which is material to governance analysis but does not itself change outstanding share count until RSUs vest and are settled.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 15,223 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- On August 15, 2025, the reporting person was awarded 15,223 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two installments of 7,612 units and 7,611 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date. The shares of common stock are held directly by Concord International, Inc. The reporting person is a controlling director of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.
FAQ
What RSUs were reported by the VNRX insider on Form 4?
When do the RSUs begin to be earned and when do they vest?
Was any cash paid for the RSU award?
What is the reporting person's relationship to VolitionRx (VNRX)?